Anti-TNF therapy safe for rheumatoid arthritis

	Tweet

When used at the recommended doses, treatment with anti-tumor necrosis factor (anti-TNF) drugs, a relatively new class of drugs for RA treatment does not increase the risk of serious adverse events, according to a report in the Annals of the Rheumatic Diseases.

At high doses, however, anti-TNF agents double the risk of serious infections, the findings suggest.

The findings stem from a review of data from 18 trials identified through a search of MEDLINE and other sources through December 2007. Included in the analysis were 8800 subjects with rheumatoid arthritis and the average follow-up period was 0.8 years. 

Treatment with anti-TNF agents at the recommended doses did not significantly increase the risks of death, serious adverse events, serious infection, lymphoma, non-melanoma skin cancers, or non-cutaneous cancers plus melanoma, lead author Dr. J. P. Leombruno, from the University of Toronto, and colleagues note.

By contrast, use of anti-TNF agents at two-to-three times the recommended doses did increase the risk of serious infections. However, further analysis showed that this risk fell as trial duration increased.

SOURCE: Annals of the Rheumatic Diseases for July 2009.

RELATED STORIES:
Over half of people with rheumatoid arthritis have periodontitis   Not Too Old for Joint Replacement   Statins show beneficial effect on rheumatoid arthritis   FDA Calls for New Study of Drug for Acute HAE Attacks   Job rates lower for people with arthritic diseases   New Therapeutic Target Identified for Rheumatoid Arthritis   The use of placebo in rheumatoid arthritis clinical trials may negatively impact patients   Bacteria Inside One’s Own Body Linked to Rheumatoid Arthritis and Other Autoimmune Diseases   Behavioral therapy may ease kids’ fibromyalgia   Heavy birthweight increases risk of developing rheumatoid arthritis   Arthritis symptoms worse in African Americans   New Pathway Involved in Rheumatoid Arthritis Identified

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]